Abstract:Background and Aims Blood metabolite abnormalities have revealed an association with cholestatic liver diseases (CLDs), while the underlying metabolic mechanisms have remained sluggish yet. Accordingly, the present evaluation aims to investigate the causal relationship between blood metabolites and the risk of two major CLDs, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Methods Univariable and multivariable Mendelian randomization (MR) approaches were employed to uncover potential causal associations between blood metabolites and 2 CLDs, including PBS and PSC, through extracting instrumental variables (IVs) for metabolites from genome-wide association studies (GWAS) conducted on European individuals. The GWAS summary data of PBC or PSC were sourced from two distinct datasets. The initial analysis employed inverse variance weighted (IVW) and an array of sensitivity analyses, followed by replication and meta-analysis utilizing FinnGen consortium data. Finally, a multivariable MR analysis was carried out to ascertain the independent effects of each metabolite. Furthermore, the web-based tool MetaboAnalyst 5.0 was used to perform metabolic pathway examination. Results A genetic causality between 15 metabolites and CLDs was recognized after preliminary analysis and false discovery rate (FDR) correction. Subsequently, 9 metabolites consistently represented an association through replication and meta-analysis. Additionally, the independent causal effects of 7 metabolites were corroborated by multivariable MR analysis. Specifically, the metabolites isovalerylcarnitine (odds ratio [OR] = 3.146, 95% confidence intervals [CI]: 1.471–6.726, p = 0.003), valine (OR = 192.44, 95%CI: 4.949–7483.27, p = 0.005), and mannose (OR = 0.184, 95%CI: 0.068–0.499, p < 0.001) were found to have a causal relationship with the occurrence of PBC. Furthermore, erythrose (OR = 5.504, 95%CI: 1.801–16.821, p = 0.003), 1-stearoylglycerophosphocholine (OR = 6.753, 95%CI: 2.621–17.399, p = 7.64 × 10 −5 ), X-11847 (OR = 0.478, 95%CI: 0.352–0.650, p = 2.28 × 10 −6 ), and X-12405 (OR = 3.765, 95%CI: 1.771–8.005, p = 5.71 × 10 −4 ) were independently associated with the occurrence of PSC. Furthermore, the analysis of metabolic pathways identified seven significant pathways in two CLDs. Conclusion The findings of the present study have unveiled robust causal relationships between 7 metabolites and 2 CLDs, thereby providing novel insights into the metabolic mechanisms and therapeutic strategies for these disorders.

Metabolic factors for liver cirrhosis: A Mendelian randomization study

The Burden of Liver Cirrhosis and Underlying Etiologies: Results from the Global Burden of Disease Study 2019

The causal relationship between gut microbiota and end-stage liver disease: a bidirectional Mendelian randomization analysis

Modifiable Lifestyle Factors, Genetic and Acquired Risk, and the Risk of Severe Liver Disease in the UK Biobank Cohort: (lifestyle Factors and SLD).

The burden of liver cirrhosis in mortality: Results from the global burden of disease study

Metabolic Dysfunction-associated Steatotic Liver Disease is Becoming the Leading Driver of the Burden of Cirrhosis in China: Results From the Global Burden of Disease Study 2019

Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study

A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry.

Genetic effects of iron levels on liver injury and risk of liver diseases: A two-sample Mendelian randomization analysis

The Causal Relationship between Inflammatory Cytokines and Liver Cirrhosis in European Descent: A Bidirectional Two-Sample Mendelian Randomization Study and the First Conclusions

Unique metabolomics characteristics for distinguishing cirrhosis related to different liver diseases: A systematic review and meta-analysis

Systemic inflammatory factors in non-alcoholic steatohepatitis-induced hepatocellular carcinoma: A bidirectional Mendelian randomization analysis

An analysis of the burden of liver cirrhosis: Differences between the global, China, the United States and India

Causal Relationship Between Gut Microbiota and Liver Cirrhosis: 16S rRNA Sequencing and Mendelian Randomization Analyses

Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China

Association of MCP-4, NRTN, and PD-L1 with the risk of hepatic fibrosis: A Mendelian randomization study

Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis

Causality of metabolites and metabolic pathways on cholestatic liver diseases: a Mendelian randomization study

Causal association between 731 immunocyte phenotypes and liver cirrhosis: A bidirectional two-sample mendelian randomization analysis

Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions

A Mendelian randomization study on the causal effects of cigarette smoking on liver fibrosis and cirrhosis